Jeremy Robertson*, Praful T. Chovatia, Thomas G. Fowler, Jonathan M. Withey and Daniel J. Woollaston
Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford, UK OX1 3TA. E-mail: jeremy.robertson@chem.ox.ac.uk; Fax: 44 1865 285002; Tel: 44 1865 275660
First published on 4th November 2009
Two routes are described for the synthesis of the sawaranospirolides, stereoisomeric spirolactone ascorbigenins isolated from Chamaecyparis pisifera. Trapping of the keto enal formed by oxidation of a functionalised 2-(4-hydroxybutyl)furan affords a potential butenolide spiroacetal precursor to sawaranospirolides A and C. Alternatively, epoxidation of protected 3-(dihydropyran-2-yl)-3-arylpropanoic acids results in spirolactonisation to generate ent-sawaranospirolide C; a related acid-mediated spirocyclisation gave access to ent-sawaranospirolide D.
![]() | ||
| Fig. 1 Sawaranospirolides A–D (Ar = p-HO–C6H4–). | ||
![]() | ||
| Scheme 1 Outline biosynthesis of sawaranospirolides A–D. | ||
![]() | ||
| Scheme 2 Access to the sawaranospirolide system by furan oxidation (Ar = p-HO–C6H4–, [P] = protecting group). | ||
We sought a synthesis of the tri-protected tetraol 4 that was efficient, convergent, and flexible in terms of the relative and absolute stereochemistry at the hydroxylated positions. Therefore, furfuraldehyde was olefinated with phosphonate 66 (Scheme 3), and the alkene (7) dihydroxylated with AD-mix-β to yield diol 8 with an ee > 98% (as inferred by Mosher's ester analysis of alcohol 12).7 After di-benzoylation (→9), reduction of the carbonyl group afforded alcohol 10 as a mixture of diastereomers.8 Direct benzoylation of the desired stereoisomer (10α) and benzoylation under Mitsunobu conditions of the undesired stereoisomer (10β),9 followed by deprotection of the primary hydroxy group, provided oxidative cyclisation substrate 12 (Scheme 4).
Oxidative spirocyclisation of this substrate with mCPBA alone4a could not be driven to the butenolide (13); however, direct treatment of the crude lactol mixture with TPAP/NMO completed the oxidation to give a high overall yield of the spirocycle as a single diastereomer. Fig. 2 summarises key 1H NMR resonances supporting the all-equatorial substitution pattern around the THP-ring.
![]() | ||
| Scheme 3 Reagents and conditions: (i) TBSCl, imidazole, DMF, 20 °C, 16 h; (ii) MePO(OMe)2, BuLi, THF, −78 °C, 2 h. | ||
![]() | ||
| Scheme 4 Reagents and conditions: (i) add to 6/NaH, THF, 0 °C, 2 h; (ii) AD-mix-β, MsNH2, aq. t-BuOH, 20 °C, 16 h; (iii) BzCl, DMAP, pyridine, CH2Cl2, 20 °C, 16 h; (iv) Zn(BH4)2, Et2O, −25 °C, 2 h; (v) BzCl, DMAP, pyridine, CH2Cl2, 20 °C, 16 h (88% from 10α); (vi) BzOH, DEAD, PPh3, C6H6, 20 °C, 48 h (57% from 10β); (vii) H2SiF6, aq. CH3CN, 20 °C, 5 min; (viii) mCPBA, CH2Cl2, 0→20 °C, 18 h then TPAP, NMO, CH2Cl2, 20 °C, 18 h. | ||
![]() | ||
| Fig. 2 Diagnostic 1H NMR coupling constants for spirolactone 13. | ||
In order to complete syntheses of sawaranospirolides A and C, all that remained at this point was to effect conjugate addition of a p-hydroxyphenyl equivalent for which various approaches were screened. We had been successful in effecting such transformations in the context of our work on the lituarines4b but substrate 13 proved to be remarkably unreactive towards conjugate addition under the mild conditions necessary to prevent degradation of the starting material, and variants of the Heck reaction and radical additions were also unproductive.10 Ultimately, this had to be abandoned and we anticipate an eventual solution to this problem to be based on oxidative spirocyclisation of a furan substrate already bearing the phenol substituent.11
![]() | ||
| Scheme 5 Synthetic strategies based on dihydropyran oxidative or acid-mediated spirolactonisation ([M] = metal, [P] = protecting group, Ar = p-hydroxyphenyl equivalent, A* = chiral carboxylic acid equivalent). | ||
Expecting that dihydropyran-2-yl cuprate reagents would be insufficiently reactive to form conjugate adducts with coumarate-type electrophiles, we assessed Meyers' 2-alkenyl-1,3-oxazolines as the chiral conjugate acceptor because these react with organolithium reagents with a predictable sense of stereoselectivity (anti addition with respect to the oxazoline substituent in an s-cis diene conformation).15 Preliminary experiments16 with model oxazoline 22 (Scheme 6) showed that 2-lithiodihydropyran was unable to generate 1,4-adducts under a variety of conditions. This led to an early revision of the strategy; viz., introduction of the p-hydroxyphenyl substituent to a pre-formed (C-1)–(C-8) system (19, pathway b, Scheme 5) to link up with the first strategy at key intermediate 16.
![]() | ||
| Scheme 6 Reagents and conditions: (i) HOCH2CH2NH2, CHCl3, 0 °C, 30 min; (ii) PPh3, DIAD, THF, 0 → 20 °C, 4.5 h; (iii) DHP-Li. | ||
Following a preliminary feasibility study,17 the sawaranospirolide synthesis was initiated by formylation and Horner–Wadsworth–Emmons reaction of dihydropyran derivative 2418 with phosphonate 3119 to give dienyloxazoline 26 in good overall yield (Scheme 7). Treatment of this acceptor with p-(benzyloxy)phenyllithium at −48 °C resulted in the formation of a single diastereomer (27)20 along with a second component, tentatively assigned as an oxidation product of the intermediate α-lithio-oxazoline. Other p-hydroxyphenyllithium equivalents (32–34, Fig. 3) also gave acceptable results in this reaction but the phenolic protecting groups were either incompatible with subsequent steps (32, 33) or did not allow release of the free phenol at the end of the synthesis (34).
![]() | ||
| Scheme 7 (i) t-BuLi, THF, −78 → 0 °C, 40 min then DMF, −78 °C, 10 h; (ii) add to 31, DBU, LiCl, CH3CN, 20 °C, 38 h; (iii) add to p-BnO–C6H4Li, THF, −48 °C, 30 min; (iv) a. MeOTf, CH2Cl2, 20 °C, 5 min; b. LiOH, aq. THF, 45 °C, 6 h; c. KOH, aq. MeOH/t-BuOH, reflux, 30 h; d. buffer (pH = 5); (v) mCPBA, CH2Cl2, 0 °C, 30 min; (vi) H2SiF6, aq. CH3CN, 20 °C, 20 h; (vii) H2, Pd/C, EtOH, 20 °C, 18 h. (Ar = p-BnO–C6H4–). | ||
![]() | ||
| Fig. 3 Reference structures and NOE data from model studies. | ||
Conditions for the overall hydrolysis of the oxazoline and subsequent oxidative spirocyclisation were optimised on a model substrate (35, Fig. 3) and, after extensive experimentation, a sequence of methyl triflate activation of the oxazoline, followed by partial hydrolysis with LiOH in warm aq. THF, gave amide 36.21 More forcing alkaline conditions completed amide hydrolysis, and acid 37 was obtained without apparent loss of stereochemical integrity, on protonation at pH 5. Pleasingly, the crucial oxidative spirocyclisation step progressed smoothly on treatment with mCPBA at 0 °C, the spirolactone (38) being isolated in 72% yield. The relative stereochemistry in this molecule was supported by 1H–1H coupling constants—all CHOH and CHOTIPS methine protons are axial, showing 3J 9.1 Hz—and the NOE interactions shown.
Application of these conditions to adduct 27 provided spirolactone 29 in 25% overall yield, somewhat down on the optimised yield obtained for the equivalent transformation in 35→38 (63%). Although we could not improve upon this yield, it was gratifying that the subsequent TIPS-deprotection and hydrogenolysis of the phenolic O-benzyl substituent proceeded efficiently to produce ent-sawaranospirolide C (30). Both 1H and 13C NMR data were in excellent agreement with those reported1 for the natural product, and the specific rotation for the synthetic material was, as expected, opposite in sign and of comparable magnitude to that reported for the natural enantiomer.
We also examined the possibility of extending this general methodology to encompass the synthesis of ent-sawaranospirolide D, the C-5 epimer of sawaranospirolide C (Scheme 8). An attempted Mitsunobu inversion at the C-5 centre (29→40) was unsuccessful; therefore, spirolactone 29 was oxidised efficiently to ketone 39 with Dess–Martin periodinane, with the intention of reducing it to the epimer (40). However, reduction of this ketone led either to return of the original alcohol (29) (with NaBH4) or non-productive reactions (with L-Selectride, Luche reduction, ‘kinetic’ Meerwein–Pondorff–Verley conditions22) and this idea was abandoned.
![]() | ||
| Scheme 8 Reagents and conditions: (i) Dess–Martin periodinane, CH2Cl2, 20 °C, 18 h; (ii) PPTS, CH2Cl2, 20 °C, 6 h; (iii) a. OsO4, TMEDA, CH2Cl2, −78 °C, 3 h then 20 °C, 12 h; b. H2S (g), THF, 0 °C, 30 min; (iv) H2SiF6, aq. CH3CN, 20 °C, 24 h; (v) H2, Pd/C, EtOH, 20 °C, 18 h. | ||
Alternatively, acid-mediated spirocyclisation of acid 28 could be achieved, albeit in only moderate yield.23 Problems in this approach included simple enol ether protonation and cyclisation, giving 5-deoxyspirolactones, or slow reactions which offered opportunities for loss of stereochemical integrity at the benzylic (C-3) position. Fortunately, both ‘anomers’ (41a,b) of the spirocyclic product could be dihydroxylated to give diols 42a,b in high yield, with the stereochemistry apparently being dictated in both cases by the bulky C-7 silyloxy substituent. The stereochemistry in these two series converged during the silyl ether deprotection and the enantiomer of the second natural product isomer, ent-sawaranospirolide D (43), was obtained after hydrogenolysis. There was again complete correspondence between the NMR data for synthetic and natural material and the respective specific rotations were of opposite signs as expected, although their magnitude differed somewhat.
In summary, we have described the first total syntheses of sawaranospirolides C and D, as their enantiomers, in 7 and 9 steps, respectively, from known glycal derivative 24.
:
1) afforded starting material (24, 102 mg, 11%) and aldehyde 25 (693 mg, 71%) as a colourless oil. Rf 0.64 (petrol/ether, 4
:
1); [α]23D−116.5 (c 1.3, CHCl3); νmax (thin film)/cm−1 1718 s, 1638 s, 1464 s, 1344 m, 1245 s, 1176 s, 1141 s, 1070 s, 923 s, 882 s, 738 s, 681 s; δH (400 MHz, CDCl3) 0.95–1.15 (42 H, m, 2 × TIPS), 3.96–3.97 (1 H, m, H-3), 4.07 (1 H, d, J 11.2, H-2), 4.16–4.19 (1 H, m, H-4), 4.21–4.25 (1 H, m, H-2′), 5.84 (1 H, dd, J 5.3, 1.5, H-5), 9.19 (1 H, s, CHO); δC (100 MHz, CDCl3) 12.3 (complex), 18.0 (complex), 64.3, 66.4, 68.8, 118.7, 151.7, 187.6; m/z (CI) 474 (MNH4+, 23%), 300 (38), 283 (100), 241 (22), 213 (17); HRMS (CI) found 474.3439, C24H52NO4Si2 (MNH4+) requires 474.3429.
:
1) to give the oxazoline 26 (3.43 g, 76%) as a viscous clear light yellow oil. Rf 0.39 (petrol/ether, 9
:
1); νmax (thin film)/cm−1 2867 s, 1640 s, 1464 s, 1385 s, 1248 s, 1143 s, 1060 s, 995 s, 921 s, 682 s; δH (400 MHz, CDCl3) 0.89 and 0.97 (2 × 3 H, 2 × d, J 6.8, oxazoline-CH(CH3)2), 0.99–1.10 (42 H, m, 2 × TIPS), 1.72–1.85 (1 H, m, oxazoline-CH(CH3)2), 3.82–3.91 (1 H, m, CH(OTIPS)CH2), 3.95–4.01 (2 H, m, OCHH′CHN), 4.02–4.06 (2 H, m, CHH′CHOTIPS and CH(OTIPS)CH=), 4.10 (1 H, br d, J 11.3, CHH′CHOTIPS), 4.22–4.32 (1 H, m, OCHH′CHN), 5.09 (1 H, d, J 4.3, =CH), 6.46 and 6.64 (2 × 1 H, 2 × d, J 15.7, CH
CH); δC (100 MHz, CDCl3) 12.4–12.7 and 17.9–18.8 (complex), 32.8, 65.2, 66.0, 69.1, 69.7, 72.6, 106.8, 115.6, 135.0, 150.3, 163.0; HRMS (ESI+) found 566.4041, C31H60NO4Si2 (MH+) requires 566.4055.
:
1) gave the title compound (27) as a colourless oil (980 mg, 86%). Rf 0.4 (petrol/ether, 4
:
1); νmax (thin film)/cm−1 2943 s, 2866 s, 1668 s, 1611 m, 1511 s, 1464 s, 1384 m, 1244 s, 1058 s, 883 s, 681 s; δH (400 MHz, CDCl3) 0.65 and 0.73 (2 × 3 H, 2 × d, J 6.7, oxazoline-CH(CH3)2), 0.95–1.10 (42 H, m, 2 × TIPS), 1.45–1.55 (1 H, m, oxazoline-CH(CH3)2), 2.76 (1 H, dd, J 14.7, 6.0) and 2.84 (1 H, dd, J 14.7, 10.2, CH2C(=N)O), 3.71–3.80 (4 H, m), 3.90–4.01 (3 H, m) and 4.05–4.12 (1 H, m, CH2CH(OTIPS)CH(OTIPS), CH2CHN and CHAr), 4.77 (1 H, d, J 5.2, =CH), 5.03 (2 H, s, CH2Ph), 6.85 and 7.20 (2 × 2 H, 2 × d, J 8.6, Ar), 7.29–7.46 (5 H, m, Ph); δC (100 MHz, CDCl3) 12.0–12.5 and 17.9–18.3 (complex), 32.2 (2 peaks), 46.1, 65.3, 66.3, 69.0, 69.7, 70.0, 71.8, 96.7, 114.4, 127.4, 127.8, 128.5, 129.2, 132.9, 137.3, 156.7, 157.5, 165.4; HRMS (ESI+) found 750.4944, C44H72NO5Si2 (MH+) requires 750.4944.
:
1) afforded a mixture of amide and ester products of oxazoline hydrolysis (595 mg, 98%) as a viscous, colourless oil. A portion of this amide/ester mixture (356 mg, 0.456 mmol) was dissolved in methanol (2.5 mL) and tert-butanol (2.5 mL) then KOH solution (4.60 mL, 2 M, 9.20 mmol) was added. The mixture was heated at reflux for 30 h then, after cooling to RT, was concentrated in vacuo, diluted with B(OH)3 solution (0.033 M, 20 mL) and extracted with dichloromethane (3 × 100 mL). The combined organic layers were dried over MgSO4 and concentrated in vacuo. This crude material was then re-dissolved in ether (50 mL) and washed with B(OH)3 solution (0.033 M, 3 × 20 mL) and brine (10 mL). The organic solution was dried over MgSO4 and concentrated in vacuo to give acid 28 as a gluey oil (256 mg, 82%) that was used in this crude form. νmax (thin film)/cm−1 3500–2500 br m, 2866 s, 1713 s, 1663 s, 1612 m, 1511 s, 1463 s, 1245 m, 883 m, 681 m; δH (400 MHz, CDCl3) 0.95–1.10 (42 H, m, 2 × TIPS), 2.79 (1 H, dd, J 16.3, 8.5) and 2.92 (1 H, dd, J 16.3, 6.7, CHCO2H), 3.75–3.88 (2 H, m) and 3.91–4.07 (3 H, m, CH2CH(OTIPS)CH(OTIPS) and CHAr), 4.76 (1 H, d, J 5.1,
CH), 5.04 (2H, s, CH2Ph), 6.90 and 7.21 (2 × 1 H, 2 × d, J 8.6, Ar), 7.31–7.48 (5 H, m, Ph); δC (100 MHz, CDCl3) 12.2–12.5 and 17.7–18.1 (complex), 29.7, 44.9, 65.0, 66.3, 68.9, 70.0, 96.9, 114.5, 127.5, 127.9, 128.6, 128.9, 133.2, 137.2, 156.3, 157.6, 177.7; HRMS (ESI+) found 683.4149, C39H63O6Si2 (MH+) requires 683.4158.
:
3) to afford spirocycle 29 (82 mg, 31%) as an oil. Rf 0.5 (petrol/ether, 6
:
4); νmax (thin film)/cm−1 3480 br m, 2945 s, 2867 s, 1785 s, 1613 m, 1514 s, 1465 m, 1383 m, 1241 m, 1090 m, 1016 m, 916 s, 884 s, 735 s, 682 s; δH (400 MHz, CDCl3) 1.02–1.20 (42 H, m, 2 × TIPS), 1.88 (1 H, d, J 9.1, OH), 2.79 (1 H, dd, J 17.1, 8.3) and 3.01 (1 H, dd, J 17.1, 12.5, CH2CO), 3.31 (1 H, t, J 9.1, CHOH), 3.57–3.66 (2 H, m, CHH′CHOTIPS), 3.69–3.76 (1 H, m, CHH′CHOTIPS), 3.85 (1H, app. t, J 8.1, CH(OTIPS)CHOH), 4.00 (1 H, dd, J 12.5, 8.3, CHAr), 5.07 (2 H, s, CH2Ph), 6.97 and 7.24 (2 × 2 H, 2 × d, J 8.8, Ar), 7.32–7.48 (5 H, m, Ph); δC (100 MHz, CDCl3) 13.4–13.6 and 18.2–18.4 (complex), 34.1, 44.6, 64.8, 70.0, 71.7, 71.8, 78.2, 108.6, 114.6, 126.1, 127.5, 128.1, 128.6, 130.5, 136.8, 158.5, 174.9; HRMS (ESI+) found 721.3929, C39H62NaO7Si2 (MNa+) requires 721.3926.
:
1) to provide the title compound (18 mg, 83%). Rf 0.2 (dichloromethane/methanol, 95
:
5); νmax (thin film)/cm−1 3600–3400 br m, 2943 s, 2866 s, 1784 s, 1514 s, 1240 m, 1109 s, 915 s; δH (400 MHz, CDCl3) 2.74 (1 H, dd, J 17.3, 8.6) and 2.97 (1 H, dd, J 17.3, 12.2, CH2CO), 3.35–3.42 (1 H, m, CH(OH)-spiro), 3.43–3.51 (1 H, m, CH2CHOH), 3.56 (1 H, app. t, J 10.8, CHH′CHOH), 3.71–3.83 (2 H, m, CHH′CH(OH)CHOH), 4.00 (1 H, dd, J 12.2, 8.6, CHAr), 4.59 (1 H, bs, OH), 4.96 (2 H, app. s, CH2Ph), 5.04 (1 H, bs, OH), 5.40 (1 H, bs, OH), 6.90 and 7.23 (2 × 2 H, J 8.5, Ar), 7.31–7.42 (5 H, m, Ph); δC (100 MHz, CDCl3) 33.9, 44.2, 64.1, 69.3, 69.9, 70.3, 75.2, 108.9, 114.6, 125.9, 127.5, 128.0, 128.6, 130.5, 136.8, 158.5, 176.1; HRMS (ESI+) found 409.1257, C21H22NaO7 (MNa+) requires 409.1258.
:
1); [α]23D +40.5 (c 1.4, MeOH), lit.1 (for enantiomer) −36 (c 2.25, MeOH); νmax (thin film)/cm−1 3600–3000 br s, 2926 m, 1769 s, 1700 m, 1651 m, 1519 s, 1367 m, 1260 m, 1105 m, 1047 m, 917 m; δH (500 MHz, d6-DMSO) 2.73 (1 H, dd, J 17.1, 8.4) and 3.01 (1 H, dd, J 17.1, 12.9, CH2CO), 3.07–3.15 (2 H, m, CH(OH)CH(OH)-spiro), 3.30 (1 H, t, J 11.3, CHH′O), overlaying 3.28–3.35 (1 H, m, CH(OH)CH2O), 3.53 (1 H, dd, J 11.3, 6.4, CHH′O), 3.89 (1 H, dd, J 12.9, 8.4, CHAr), 5.01 (1 H, d, J 6.0, one of CH(OH)CH(OH)-spiro), 5.13 (1 H, d, J 6.0, CH(OH)CH2O), 5.74 (1 H, d, J 6.0, one of CH(OH)CH(OH)-spiro), 6.70 and 7.12 (2 × 2H, 2 × d, J 8.5, Ar), 9.40 (1 H, br s, ArOH); δC (125 MHz, d6-DMSO) 32.6, 43.3, 64.2, 69.0, 69.7, 74.3, 108.7, 114.8, 124.8, 130.2, 156.6, 175.1; HRMS (FI+) found 296.0901, C14H16O7 (M+) 296.0891.
:
1) to give ketone 39 (29 mg, 83%) as a colourless oil. Rf 0.82 (petrol/ether, 4
:
1); νmax (thin film)/cm−1 2947 s, 1814 s, 1752 s, 1614 m, 1514 s, 1464 s, 1383 m, 1124 s, 899 m, 793 m; δH (400 MHz, CDCl3) 1.03–1.12 (42 H, m, 2 × TIPS), 2.88 (1 H, dd, J 17.5, 8.7) and 3.00 (1 H, dd, J 17.5, 11.8, CH2CO), 3.87–4.02 (3 H, m, CH2CHO), 4.31 (1 H, dd, J 11.8, 8.7, CHAr), 4.82 (1 H, dd, J 4.8, 3.7, CHCO),25 5.06 (2 H, s, CH2Ph), 6.94 and 7.26 (2 × 2 H, 2 × d, J 8.8, Ar), 7.31–7.47 (5 H, m, Ph); δC (100 MHz, CDCl3) 12.9–13.1 and 18.0–18.2 (complex), 33.9, 42.7, 65.4, 70.0, 75.1, 81.4, 105.4, 114.5, 125.9, 127.5, 128.0, 128.6, 130.6, 136.8, 158.3, 173.4, 196.5; HRMS (ESI+) found 787.4747, C42H71N2O8Si2 (M·CH3CN·MeOH·NH4+) requires 787.4743.
:
1) afforded spirocycles 41a (22 mg, 24%) and 41b (12 mg, 13%) as oils. Data for 41a: Rf 0.53 (petrol/ether, 7
:
3); νmax (thin film)/cm−1 2942 s, 2890 s, 1784 s, 1659 m, 1612 m, 1583 m, 1514 s, 1463 m, 1427 m, 1400 m, 1383 m, 1245 s, 781 s; δH (400 MHz, CDCl3) 1.04–1.12 (21 H, m, TIPS), 2.77 (1 H, dd, J 17.5, 5.1) and 3.25 (1 H, dd, J 17.5, 8.6, CH2CO), 3.73 (1 H, dd, J 8.6, 5.1, CHAr), 3.98 (1 H, d, J 12.1, CHH′O), 4.04–4.07 (1 H, m, CHOTIPS), 4.15 (1 H, dd, J 12.1, 2.6, CHH′O), 5.05 (2 H, s, CH2Ph), 5.30 (1 H, d, J 10.2) and 6.02 (1 H, ddd, J 10.2, 5.2, 1.0, CH
CH), 6.94 and 7.13 (2 × 2 H, 2 × d, J 8.7, Ar), 7.32–7.47 (5 H, m, Ph); δC (100 MHz, CDCl3) 12.3, 18.0 (2 peaks), 35.2, 49.7, 61.0, 68.4, 70.0, 106.0, 115.0, 125.3, 127.5, 128.1, 128.6, 128.9, 129.4, 131.0, 136.8, 158.3, 175.6; HRMS (ESI+) found 509.2717, C30H41O5Si (MH+) requires 509.2718. Data for 41b: Rf 0.45 (petrol/ether, 7
:
3); νmax (thin film)/cm−1 2943 s, 2867 s, 1799 s, 1514 s, 1463 m, 1395 m, 1221 s, 1181 s, 1125 m, 899 m, 688 m; δH (400 MHz, CDCl3) 0.98–1.10 (21 H, m, TIPS), 2.78 (1 H, dd, J 16.9, 7.9) and 3.13 (1 H, dd, J 16.9, 12.9, CH2CO), 3.57 (1 H, dd, J 12.9, 7.9, CHAr), 3.69 (1 H, t, J 10.3) and 3.80 (1 H, dd, J 10.3, 5.7, CH2O), 3.99–4.07 (1 H, m, CHOTIPS), 5.06 (2 H, s, CH2Ph), 5.78 (1 H, dd, J 10.2, 1.9) and 6.14 (1 H, d, J 10.2, CH
CH), 6.94 and 7.18 (2 × 2 H, 2 × d, J 8.7, Ar), 7.32–7.46 (5 H, m, Ph); δC (100 MHz, CDCl3) 12.1–12.3 and 17.9–18.0, 33.5, 50.1, 62.9, 65.5, 70.0, 104.5, 114.5, 124.7, 126.7, 127.5, 128.1, 128.6, 129.6, 136.8, 139.1, 158.3, 175.1; HRMS (ESI) found 509.2723, C30H41O5Si (MH+) requires 509.2718.
:
2) to give diol 42a (35 mg, 85%) as an oil. Rf 0.67 (dichloromethane/methanol, 95
:
5); νmax (thin film)/cm−1 3600–3300 br m, 2941 s, 2865 s, 1774 s, 1513 s, 1456 s, 1238 s, 1124 s, 1054 s, 845 s; δH (500 MHz, CDCl3) 0.95–1.05 (21 H, m, TIPS), 2.31 (1 H, br s, OH), 2.55 (1 H, br s, OH), 2.85 (1 H, dd, J 17.1, 9.2) and 3.32 (1 H, dd, J 17.1, 12.8, CH2CO), 3.71 (1 H, dd, J 12.8, 9.2, CHAr), 3.73 (1 H, br s, CH(OH)-spiro) overlaying 3.78 (1 H, d, J 12.6, CHH′O), 3.80 (1 H, br s, CH(OH)CHOTIPS), 3.99 (1 H, d, J 3.6, CHOTIPS), 4.21 (1 H, d, J 12.6, CHH′O), 5.06 (2 H, AB q, J 11.8, CH2Ph), 6.96 and 7.33 (2 × 2 H, 2 × d, J 8.7, Ar), 7.30–7.46 (5 H, m, Ph); δC (125 MHz, CDCl3) 12.1–12.2 and 17.9 (2 peaks), 34.3, 50.8, 64.0, 64.6, 70.0, 70.1, 71.7, 110.7, 115.0, 126.6, 127.4, 128.0, 128.6, 129.1, 136.9, 158.5, 173.4; HRMS (ESI+) found 565.2580, C30H42NaO7Si (MNa+) requires 565.2592. Analogously, from 41b (28 mg, 55.1 μmol), diol 42b was obtained (25 mg, 84%). Rf 0.79 (dichloromethane/methanol, 95
:
5); νmax (thin film)/cm−1 3500–3100 br m, 2926 s, 1773 s, 1513 s, 1245 m, 1038 m; δH (400 MHz, CDCl3) 1.02–1.06 (21 H, m, TIPS), 2.29 and 2.50 (2 × 1 H, 2 × br s, 2 × OH), 2.85–2.95 (2 H, m, CH2CO), 3.63 (1 H, t, J 10.3, CHH′O), 3.75–3.85 (2 H, m, CHAr and CHH′O), 3.88–3.97 (2 H, m, 2 × CHOH), 4.08 (1 H, d, J 2.3, CHOTIPS), 5.05 (2 H, s, CH2Ph), 6.94 and 7.32 (2 × 2 H, 2 × d, J 8.7, Ar), 7.34–7.46 (5 H, m, Ph); δC (100 MHz, CDCl3) 12.1 (2 peaks) and 17.9 (3 peaks), 36.3, 48.2, 65.1, 67.8, 69.9, 73.0, 73.7, 106.8, 114.3, 127.5, 128.0, 128.6, 130.8, 136.9, 158.2, 174.3; HRMS (ESI+) found 543.2789, C30H43O7Si (MH+) requires 543.2773.
:
2) to give the title compound (11 mg, 44%) as an oil. [The same compound was obtained in similar yield by the analogous reaction of diol 42b (25 mg, 46.1 μmol).] Rf 0.36 (dichloromethane/methanol, 95
:
5); νmax (thin film)/cm−1 3700–3100 br m, 3079 s, 1784 m, 1616 s, 1543 s, 1229 s, 1035 m, 1012 m, 816 m, 682 m; δH (400 MHz, CD3OD) 2.90 (2 H, app. d, J 9.8, CH2CO), 3.49 (1 H, app. ddd, J 14.9, 7.4, 2.9, CHH′O), 3.66–3.81 (3 H, m, CHH′O and CH(OH)CH(OH)-spiro), 3.83 (1 H, t, J 9.8, CHAr), 3.95 (1 H, d, J 3.2, CH2CHOH), 5.07 (2 H, s, CH2Ph), 6.90 and 7.31 (2 × 2 H, 2 × d, J 8.6, Ar), 7.34–7.46 (5 H, m, Ph); δC (100 MHz, CD3OD) 36.2, 48.0, 65.3, 65.9, 69.9, 72.2, 73.9, 108.6, 114.2, 127.5, 127.8, 128.5, 129.6, 131.0, 137.9, 158.3, 175.6; HRMS (FI+) found 386.1359, C21H22O7 (M+) requires 386.1366.
:
1); [α]23D +28.7 (c 0.4, MeOH), lit.1 (for enantiomer) −54 (c 0.74, MeOH); νmax (thin film)/cm−1 3650–3100 br s, 2925 m, 1771 s, 1615 m, 1519 s, 1260 s, 1024 m, 960 m; δH (400 MHz, d6-DMSO) 2.75 (1 H, dd, J 17.7, 9.8) and 2.90 (1 H, dd, J 17.7, 9.2, CH2CO), 3.25 (1 H, t, J 10.1, CHH′O), 3.47–3.61 (3 H, m, CHH′CH(OH)CH(OH)), 3.70–3.82 (2 H, m, CH(OH)-spiro and CHAr), 4.36, 4.88 and 5.01 (3 × 1 H, 3 × br s, 3 × OH), 6.62 and 7.10 (2 × 2 H, 2 × d, J 8.6, Ar); δC (100 MHz, d6-DMSO) 35.8, 46.3, 65.1, 65.4, 71.3, 72.9, 108.3, 114.2, 127.8, 130.7, 156.0, 174.3; HRMS (FI+) found 296.0888, C14H16O7 (M+) requires 296.0896.
Footnote |
| † Electronic supplementary information (ESI) available: Experimental details for Schemes 3, 4 and 6; copies of selected 1H and 13C NMR spectra for the compounds in Schemes 7 and 8. See DOI:10.1039/b918091e |
| This journal is © The Royal Society of Chemistry 2010 |